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Background: The current and general safety control tests for vaccines have been the use several animal
tests. Vaccine is considered safe if it does not cause weight loss or death in laboratory animals at human
dose, does not promote leukocytosis by a factor P10 and showed a Leukopenic toxicity value P80% of
the Leukopenic toxicity of the control. The study sets to determine the safety of routine immunization
vaccines from Anambra, Ebonyi and Enugu states of Nigeria and indirectly evaluate the efficiency of
cold-chain facilities.
Method: The study was designed to check the safety of the routine immunization vaccines to the
hematopoietic system of mice and mice body weight changes after immunization.
Results: Animal body weight changes test showed that the mice immunized with the vaccines increased
in weight at days 3 and 7 post-immunization and exceeded 60% weight gain at day 7 post-immunization.
None of the mice died during the observation period. Hematopoietic system toxicity tests showed that
the vaccines are non- toxic.
Conclusion: The vaccines were generally safe and non-toxic. The cold-chain systems in the States studied
were efficient and had not compromised the safety of the vaccines.
 2015 The Authors. Published by Elsevier Ltd. This is anopenaccess article under the CCBY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Vaccines play a vital role in preventive medicine [1]. Vaccine
safety is a prime concern to everybody yet no biological or pharma-
ceutical product ever developed and produced is completely safe
and one hundred per cent effective [2]. As a vaccine becomes safer,
it becomes less effective [3]. Vaccine development and licensing is
usually expensive as well as time consuming. The discovery of
effective and reliable method of identifying the safest and most
effective vaccine candidate at the early stage would be highly use-
ful [4]. The European Union recommends that both live and killed
vaccines be considered safe only after testing according to laid
down procedures. They recommend that the assessment of safety
in the target species should be based on clinical reaction and labo-
ratory animals’ weight gain compared with unvaccinated controls[5]. Animal body weight change test is the most commonly used
test to evaluate the toxicity of vaccines. The issue of vaccine safety
has discouraged some parents and care-givers, both in developed
[6–8] and developing countries [9,10], from immunizing their chil-
dren and wards. Reassurance of vaccine safety is therefore, vital for
population health [6]. Vaccines are biological products and the
slightest breech in the cold-chain may make them unsafe for use
in immunization programme. Nigeria, like other developing
countries of the world, is besieged with the problem of unreliable
power supply. This heightens the safety question. In view of the
questionable power supply in the country, it is necessary to carry
out a sporadic evaluation of the cold-chain system where these
thermo labile and live-saving products are stored.
2. Method
2.1. Study area
Anambra, Ebonyi and Enugu states are located in the South-east
geo-political zone of Nigeria. The states are predominantly Ibo by
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nes from Abuja via the national allocation. Each state has only one
central cold-chain store for vaccine storage and distribution. From
there, the vaccines are distributed to the Local Government areas
which then feed the immunization centers. Our study concerns
the central cold-chain stores in the three of the five states that
make the south-east states of Nigeria.2.2. Vaccines collection and storage
The Expanded Programme on Immunization (EPI) vaccines were
donated by the Ministries of Health of Ebonyi, Enugu and Anambra
States. Vaccines were transported in an insulated vaccines carrier
and stored in the storage facility of Nnamdi Azikiwe University
Teaching Hospital, Nnewi within 4 h of collection. Temperature
at collection was 4 ± 1 C and before storage 5 ± 1 C. Study was
conducted within 1 month of vaccine collection and the tempera-
ture of the storage facility was charted daily while vaccine storage
lasted.3. Animals used
Albino mice, gender balanced, of weight 12–28 g were accom-
modated under standard conditions (temperature: 26 ± 2 C, rela-
tive humidity: 45 ± 2%) and provided with standard pellet diet
and water. The study was carried out in Pharmacology and Toxicol-
ogy Laboratory of Faculty of Pharmaceutical Sciences, Nnamdi Azi-
kiwe University, Agulu Campus and in hematology laboratory of
Nnamdi Azikiwe University Teaching Hospital, Nnewi. The
research protocols were approved by the Research and Ethics Com-
mittee of Nnamdi Azikiwe University Teaching Hospital, Nnewi
(Approval #: NAUTH/CS/66/Vol.4/220).3.1. Mouse identification
Two basic methods exist for the labeling of the animals used in
biomedical research. They are temporary identification methods
and permanent identification methods [11,12]. For convenience
and skill, the temporary identification method was used in this
study and the marks were renewed every other day. The animals
(age = 20 ± 5 days) used in the study were treated in accordance
with the Guidelines stated in the Animal Welfare Act [13] and Aus-
tralian Government [14].4. Determination of the toxicity and safety levels of the vaccines
This was done, with some modifications; using the method
described by Haruka et al [15].4.1. Animal body weight changes test
A total of 70 mice grouped into 7 with each group containing 10
mice of equal sex were used. A human dose of OPV, DPT (or
pentavalent), BCG, Measles, YFV and HBV was injected into the
peritoneum (except for OPV which was by oral route) of mice in
group 1–6 respectively. Group 7 animals were given 0.5 ml of
0.9% sodium chloride. All the mice were observed daily for 7 days.
A good vaccine should not [16,17] (i) cause a decrease in the
weight of the mice 3 days post-vaccination, (ii) produce a less than
60% mean weight gain per mice compared with the control at
7 days post-vaccination (iii) produce greater than 5% animal dead
during the 7 days observation period nor any sign of illness on
the animals [16].4.2. Leukocytosis-promoting toxicity test
The toxicity of the vaccines to the hematopoietic system was
tested using Haruka et al. [15] method and modified by Oli et al.
[20]. Briefly, heparinized capillary tube was inserted just below
the eyeball of the mice prior to immunization and 3 days after to
allow 1–2 drops of blood flow onto a sterile microscope slide. With
a 20 ml micropipette, 20 ml blood samples was picked from the slide
and dropped into a sterile eppendoff tube containing 380 ml Turk’s
solutions. The leukocytes (White Blood Cells) count was done using
Heamocytometer. The vaccines were considered safe if the mean
peripheral blood leucocyte count 3 days post-immunization is
not more than 10 fold pre-immunization [16].
4.3. Leukopenic toxicity test in vaccinated animals
This also tests the toxicity of the vaccines to the hematopoietic
system using the general safety test and the leukopenic toxicity
test (LTT). The animals used for the body weight changes test were
also used for the Leukocytosis-promoting toxicity test. The 8th
group was given cyclophosphamide (400 mg/kg) [18] by gavage
to serve as positive control. Cyclophosphamide for injection was
reconstituted with the 0.9% Sodium Chloride Injection to make a
stock solution of 20 mg/ml (Make: Biochem Pharmaceutical Indus-
tries LTD, India – Lot #: KB116010). Eighteen hours later, 20 ll
blood samples of the mice were collected in sterile eppendoff tube
using heparinized capillary tube inserted just below the eye ball,
diluted with Turk’s solution (380 ll) and leukocytes (White Blood
Cells) count done using Heamocytometer. The vaccine is consid-
ered safe if it shows a Leukopenic toxicity value greater than or
equal to 80% of the Leukopenic toxicity of the control [15,16,19].
Leukopenic toxicity ½20 ¼ WBC count ðTest or ControlÞ
WBC count ðToxic SubstanceÞ4.4. Statistical analysis
The results were analyzed using GraphPad Prism version 5.00
for Windows, GraphPad Software, Inc. San Diego California USA,
www.graphpad.com”. Continuous variables (weights) were com-
pared with baseline using unpaired t test. One-way ANOVA or
the non-parametric equivalent was used to compare continuous
variables in groups. Two-way ANOVA was used to compare how
the continuous variables respond to the effect of two factors
(length of time post-vaccination and the different vaccines). Dun-
nett’s Tests of Multiple Comparison and Bartlett’s test for equal
variances were also carried out. All p values reported are for a
one-tailed test. The significance level was chosen at a = 0.05.
4.5. Results presentation
None of the mice used in the study showed any sign of abnor-
mality or ill health throughout the 7 days post-immunization
observation. There was no weight loss and none died.
As shown in Table 1, the animals immunized with the vaccines
all showed on the average some increase in weight gain and the
percentage weight gain compared with the mice immunized with
0.9% sodium chloride (the control) was greater than 60%. However,
the values given by the measles, yellow fever and hepatitis B vac-
cines were marginally above the cut-off. Dunnett’s Multiple Com-
parison Test to compare the mean body weights of the
immunized mice with that of the control showed that at day 3
post-vaccination, all the mice except those immunized with DPT
and BCG, had non-significant weight gain at p < 0.005.
At day 7 post-vaccination, the mice immunized with OPV, DPT
and BCG had significant weight gain while those immunized with
Table 1
Animal body weight changes test for vaccines from Ebonyi and Enugu states.
Vaccines Day after
vaccination
Mice body weight (g) % Wt. gain compared to mean Wt. gain of
control
p Value*
(<0.05 = significant)
Total
weight
Mean weight
(n = 10)
Mean weight
gain
OPV 0 177.3 17.73 0.00
3 183.3 18.33 0.60 0.338
7 241.3 24.13 6.40 118.430034 <0.0001
DPT 0 216.6 21.66 0.00
3 220.8 22.08 0.42 0.4134
7 275.3 27.53 5.87 100.341297 <0.0001
BCG 0 212.8 21.28 0.00
3 214.9 21.49 0.21 0.4443
7 280.4 28.04 6.76 130.716724 0.0002
Measles 0 153.6 15.36 0.00
3 170.5 17.05 1.69 0.0387
7 201.1 20.11 4.75 62.116041 0.0004
YFV 0 156.4 15.64 0.00
3 166.9 16.69 1.05 0.0014
7 204.8 20.48 4.84 65.1877133 <0.0001
HBV 0 159.4 15.94 0.00
3 168.9 16.89 0.95 0.2573
7 208.5 20.85 4.91 67.5767918 0.0011
Control
NS
0 145.2 14.52 0.00
3 155.1 15.51 0.99 0.1100
7 174.5 17.45 2.93 0.0022
Note: day 0 means before vaccination, x = % mean weight gain compared to control (7 days post-vaccination),
* p value is for student t-test.
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weight gain at p < 0.05. A two-way analysis of variance of the result
of the body weight changes test showed that vaccine type and
post-vaccination day significantly affected the weight of the ani-
mals (p value <0.0001) but the interactive effect of both do not
(p value = 0.5308).
Table 2 shows the result of leukocytosis-promoting toxicity test
for the vaccines collected from Enugu/Ebonyi States. The vaccines
are considered non-toxic if it does not promote leukocytosis by a
factor P10 [16].
The leukocytosis-promoting toxicity study performed on the
vaccines (Table 2) revealed that all the vaccines were able toTable 2
Leukocytosis-promoting toxicity test for vaccines from Enugu/Ebonyi.
Vaccines Day after
vaccination
Leukocyte count of
the mice ( 109/L)
WBC Increased
by X folds
p
Value*
Total
WBC
Mean WBC
(n = 10)
OPV a 42.90 4.290 2.30 <0.0001
b 98.55 9.855
DPT a 63.05 6.305 3.23 <0.0001
b 203.95 20.395
BCG a 48.00 4.800 2.01 <0.0001
b 96.35 9.635
Measles a 49.80 4.980 2.12 0.002
b 105.42 10.542
YFV a 53.95 5.395 2.13 0.004
b 114.65 11.465
HBV a 48.5 4.85 2.16 0.001
b 104.65 10.465
Control
NS
a 49.80 4.980 2.21
b 110.25 11.025
Note: a = before vaccination, b = 3 days after vaccination and control NS = control
using 0.9% normal saline.
* p value (for Student t-test) < 0.05 = significant.increase the leukocyte count in vaccinated animals by at least
two fold. The DPT increased the count by three fold. None of the
vaccines studied produced up to ten fold increase in the leukocyte
count. Also, the vaccines produced about the same effect (increase
in the leukocyte count) compared with the control showing that
they are safe. This is confirmed by the Dunnett’s Multiple Compar-
ison Test which compared the effect of each vaccine with the con-
trol at p < 0.05. It may be deduced from the study that the vaccines
might not have likely affected the hematopoietic system adversely.
A t-test analysis of the data showed significant difference in the
mean WBC count at pre- and post-vaccination of the mice with
the vaccines studied.
The two-way ANOVA of the leukocytosis-promoting toxicity
test showed that the vaccine type, the post-vaccination day and
their interaction all affected the WBC count of the animals (p value
<0.0001). The interaction accounts for 9.13% of the total variations
in the leukocyte count. The vaccine type accounts for 16.76% while
the post-vaccination day accounts for 47.59% variations.
The Fig. 1 shows the leukopenic toxicity test in mice. The vacci-
nes are considered non-toxic if they show Leukopenic toxicity val-
ues greater than or equal to 80% of the Leukopenic toxicity of the
control. The leukopenic toxic reference used was cyclophos-
phamide (Control Cp) while the leukopenic non-toxic reference
was 0.9% sodium chloride. The leukopenic Toxicity values of the
test vaccines and the 0.9% sodium chloride were OPV – 2.713,
DPT – 2.655, BCG – 2.825, Measles – 2.879, Yellow fever – 2.654,
Hepatitis B – 2.629 and sodium chloride – 3.143. The leukopenic
Toxicity value of each of the vaccines was higher than the 80%
leukopenic Toxicity value of control NS (Fig. 1). Analysis of the
mean leukocyte counts using one way ANOVA shows significant
difference (p < 0.0001) in the leukocyte counts due to cyclophos-
phamide compared with the vaccines. Bartlett’s test for equal
variances also showed that their variances also differ significantly
(p value = 0.0018).
The Dunnett’s multiple comparison tests for the vaccines
showed that the mean leukocyte count in the mice produced by
the vaccines and the 0.9% sodium chloride were each significantly
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Fig. 1. Leukopenic test for vaccines from Ebonyi/Enugu states. Leukopenic
toxicity = WBC count (Test or Control)/WBC count (Toxic Substance). Values
represent the leukopenic toxicity values of the vaccines as a percentage of the
leukopenic toxicity value of the control (0.9% NaCl).
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comparison of the leukocyte count due to the 0.9% sodium chloride
and that due to the vaccines using one way ANOVA showed no sig-
nificant difference (p value = 0.9090). The vaccines were as safe as
the normal saline. This is confirmed by the Dunnett’s Multiple
Comparison. The One-way analysis of the leukopenic toxicity value
showed that the leukocyte count is significantly affected by all the
treatments (p value <0.0001) – the vaccines, the normal saline and
the cyclophosphamide while the Bartlett’s test for equal variances
showed that the variances are also significantly different.
All the animals used in this study survived with no sign of ill
health. A comparison of the mean body weight at pre- and post-
vaccination days (Table 3) showed that there was generally
non-significant weight gain except in the group immunized with
hepatitis B vaccine on day 3 post-vaccination but significant
weight gain in all on day 7 post-vaccination at p < 0.05. All theTable 3
Animal body weight changes test for vaccines from Anambra state.
Vaccines Day after vaccination Mice body weight (g)
Total weight Mean weight (n = 10)
OPV 0 186.3 18.63
3 214.2 21.42
7 243.5 24.35
Pentavalent 0 198.3 19.83
3 203.9 20.39
7 249.4 24.94
BCG 0 183.2 18.32
3 192.7 19.27
7 235.4 23.54
Measles 0 167.7 16.77
3 173.9 17.39
7 229.3 22.93
YFV 0 199.8 19.98
3 200.8 20.08
7 268.7 26.87
HBV 0 147.0 14.70
3 159.2 15.92
7 196.4 19.64
Control 0 165.8 16.58
3 172.2 17.22
7 196.5 19.65
Note: day 0 means before vaccination.
* p value is for student t test.vaccines produced beyond 60 per cent weight gain in the immunized
mice the least being HBV (60.91%) followed by Pentavalent vaccine
(66.45%). The significance of this is that both the hepatitis B and
pentavalent vaccines should be used in the shortest possible time.
Dunnett’s Multiple Comparison Test showed that at day 3 post-
vaccination, all the mice immunized had non-significant weight
gain at p < 0.05 except those immunized with OPV, compared with
the control. At day 7 post-vaccination, all the mice have significant
weight gain at p < 0.05 compared with the control.
Two-way ANOVA of the result showed that both the vaccine
type and the post-vaccination day significantly affected the ani-
mals’ body weight (p values <0.0001) by 23.69% and 26.12% but
the interactions between the two do not (p value = 0.8196). The
vaccine type does not have the same effect at all values affected
by post-vaccination days. The interactions accounted for only
1.91% of the total variance.
Leukocytosis-promoting toxicity test (Table 4) showed that the
vaccines produced less than 2 fold increase in the WBC count
between the pre- and post-vaccination period. The increase was
well comparable with that of the control. Neither the vaccines
nor the control produced as much as ten folds increase in the
WBC. A t test analysis showed significant difference, at p < 0.05,
in the effects produced the vaccines when compared with pre-
vaccination period with the exception of BCG. The Dunnett’s mul-
tiple comparison tests showed that the effects produced by the
vaccines were not significantly different from that produced by
the control.
Two-way ANOVA of the leukocytosis-promoting test showed
also that vaccine type as well as post-vaccination day affected
the leukocyte count (p value = 0.003 and <0.0001 respectively) by
11.84% and 16.96% respectively. The vaccine type did not have
the same effect at all values of the leukocyte count affected by
post-vaccination day. The interactions of the two produced only
0.46% of the total variations.
The vaccines (procured from Anambra State) and the sodium
chloride had LTvalues of 3.362, 3.603, 3.611, 3.356, 3.295, 3.624
and 3.998. The LTvalue of each of the vaccines was higher than the% Wt. gain compared to
mean Wt. gain of control
p value* (<0.05 = significant)
Mean weight gain
0
2.79 0.114
5.72 86.3192182 0.0021
0
0.56 0.3227
5.11 66.4495114 0.0005
0
0.95 0.3316
5.22 70.0325733 0.0066
0
0.62 0.2475
6.16 100.651466 0.0003
0
0.1 0.4789
6.89 124.429967 0.001
0
1.22 0.1042
4.94 60.9120521 <0.0001
0
0.64 0.1419
3.07 <0.0001
Table 4
Leukocytosis-promoting toxicity test for vaccines from Anambra state.
Vaccines Day after vaccination Leukocyte count of the
mice ( 109/L)
WBC increased by X folds p value*(<0.05 = significant)
Total WBC Mean WBC (n = 10)
OPV a 43.00 4.300 1.5639535 0.0015
b 67.25 6.725
Pentavalent a 71.35 7.135 1.3398739 0.0235
b 95.60 9.560
BCG a 52.20 5.220 1.5354406 0.086
b 80.15 8.015
Measles a 45.25 4.525 1.6099448 0.0038
b 72.85 7.285
YFV a 66.60 6.660 1.3528529 0.0209
b 90.10 9.010
HBV a 50.60 5.060 1.3488142 0.0069
b 68.25 6.825
Control NS a 59.20 5.920 1.3032095 0.0275
b 77.15 7.715
Note: a = before Vaccination, b = 3 days after vaccination.
* p value is for student t-test.
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Fig. 2. Leukopenic test for vaccines from Anambra state. Leukopenic toxicity = WBC
count (Test or Control)/WBC count (Toxic Substance). Values represent the
leukopenic toxicity values of the vaccines as a percentage of the leukopenic
toxicity value of the control (0.9% NaCl).
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mean leukocyte counts shows significant difference (p < 0.0001)
between the cyclophosphamide and the vaccines. Also, Bartlett’s
test for equal variances shows that their variances differ
significantly.
The Dunnett’s multiple comparison tests confirmed the signifi-
cant differences in the mean leukocyte counts of the vaccines com-
pared with cyclophosphamide but no significant difference when
the vaccines and the sodium chloride were compared at p < 0.05.
One-way ANOVA of the leukopenic toxicity test shows that the
leukocyte count is significantly affected by all the treatments
(p value < 0.0001). Bartlett’s test for equal variances also show that
the variances are also significantly different (p value = 0.0016).
Dunnett’s Multiple Comparison Test showed that the mean leuko-
cyte count produced by the leukopenic agent – cyclophosphamide
is significantly different from that produced by the vaccines.
The vaccines have the same effects as the physiological saline
(p value = 0.0346).5. Discussions of results
Immunization with potent and safe vaccines has been reported
to be responsible for the reduction in cases infectious diseases out-
break in all age groups [6,21]. Tables 1 and 3 showed the results
from animal body weight changes tests. The results showed that
the vaccines were safe. However, some vaccines were marginally
above the cut-off. The significance of this is that those vaccines,
although still safe at the time of collection, should be used up
quickly or they risk being unsafe.
That the vaccines were safe could be attributed to the absence
of residual toxin and/or chemicals in the vaccines and non-
formation of degradation products in the vaccines which results
from poor vaccine storage. Two independent groups of researchers
[22,23] were able to prove that the Pertussis-containing vaccines
that lower animal body weight could cause adverse reactions if
administered to children. The safety of vaccines utilized in routine
immunization of US children was reported [6]. Another group of
researchers [24] showed that the results of abnormal toxicity test
correlates well with vaccine toxicity. Generally, the vaccines that
showed P100% weight gain (in the immunized mice 7-days
post-vaccination) compared to mean weight gain of control mice)
have better safety profile.
Tables 2 and 4 showed the results of the leukocytosis promoting
test conducted on the vaccines. The leukocytosis-promoting toxic-
ity test showed that none of the vaccines from the states were able
to produce up to ten fold increase of the white blood cells in the
animals used for the study. This compares well with the control
showing that the vaccines did not cause any hematopoietic dam-
age. There effect to the hematopoietic system was as good as the
physiological saline used as the control. A study [25] demonstrated
that leukocytosis promoting test was better than the mouse body
weight changes test in testing for the safety of Whole Cell Pertussis
Vaccine. Another study [26] suggested that gene expression analy-
sis of vaccine-treated animals is as accurate as leukocytosis-
promoting toxicity test in assessing pertussis vaccine safety.
Figs. 1 and 2 showed the results of the leukopenic toxicity test.
This test demonstrated whether or not the vaccines are capable of
inducing leucopenia (decrease in the number of white blood cells
(leukocytes) found in the blood) thus placing vaccinated
individuals at increased risk of infection. From the test of statistics
(Dunnett’s multiple comparison tests) used in the analysis, the
A.N. Oli et al. / Trials in Vaccinology 5 (2016) 8–14 13vaccines were found to be similar to the non-toxic reference (0.9%
sodium chloride) used and significantly different (p value < 0.05)
from the toxic reference (the cyclophosphamide). It is therefore
concluded that the vaccines are not capable of decreasing the num-
ber of WBC and so are safe. As a comparison with certain drugs,
two groups of researchers [16,27] demonstrated that chloram-
phenicol at the dose of 3500 mg/kg and cyclophosphamide at the
dose of 250 mg/kg respectively was leukopenic to mice.
5.1. Study limitations
This study was a one-point study in that the vaccines were col-
lected at one particular time. It could not give a true picture of the
cold-chain facilities over time. None of the vaccines could be eval-
uated on the day of collection because of poor access road and
other logistic problems. However, efforts were made to monitor
vaccine temperature throughout the study.
5.2. Conclusion
The EPI vaccines in this study were generally safe and have tox-
icity profiles comparable to Sodium Chloride 0.9%. The cold-chain
systems in Anambra, Ebonyi and Enugu states were efficient as
at the time of vaccine collection. The safety of the vaccines were
not yet compromised.
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